NasdaqGM - Nasdaq Real Time Price USD

Iovance Biotherapeutics, Inc. (IOVA)

1.7500

-1.4200

(-44.79%)

At close: May 9 at 4:00:02 PM EDT

1.7497

-0.00

(-0.02%)

After hours: May 9 at 7:59:41 PM EDT

3 Monster Stocks in the Making

Axsome Therapeutics is taking off, led by a treatment for major depressive disorder. Iovance Biotherapeutics could transform how solid tumors are treated. Here's why they think Axsome Therapeutics (NASDAQ: AXSM), Iovance Biotherapeutics (NASDAQ: IOVA), and Viking Therapeutics (NASDAQ: VKTX) are monster stocks in the making.

Motley Fool 13 hours ago

VKTX

IOVA
-44.79%

AXSM
Iovance Biotherapeutics First Quarter 2025 Earnings: Misses Expectations

Iovance Biotherapeutics ( NASDAQ:IOVA ) First Quarter 2025 Results Key Financial Results Revenue: US$49.3m (up by...

Simply Wall St. yesterday

IOVA
-44.79%
Iovance Biotherapeutics Stock Sinks 46%. Here’s Why the Biotech Is Tumbling.

Iovance Biotherapeutics stock was tumbling Friday after the oncology drug maker posted a wider-than-expected first-quarter loss. Management pinned the disappointing first-quarter results on reduced production capacity due to annual maintenance at its Iovance Cell Therapy Center. “Since full production has now resumed at the [Cell Therapy Center], we now expect infusions to grow in the second quarter as compared to the first quarter,” said interim CEO Frederick Vogt.

Barrons.com 2 days ago

IOVA
-44.79%
Why Iovance Biotherapeutics Stock Is Crashing Today

Iovance's Q1 revenue was sharply lower than expected. The company blamed the miss on lower production capacity due to annual maintenance at its cell therapy facility. Shares of Iovance Biotherapeutics (NASDAQ: IOVA) were crashing 46.6% lower as of 10:40 a.m. ET on Friday.

Motley Fool 2 days ago

IOVA
-44.79%
Iovance's Q1 Earnings & Sales Miss, Stock Slides 39% on '25 View Cut

IOVA reports dismal first-quarter results. The share price plunges after the company significantly lowers its 2025 sales guidance.

Zacks 2 days ago

IOVA
-44.79%
Iovance Biotherapeutics Inc (IOVA) Q1 2025 Earnings Call Highlights: Strong Revenue from Antagy ...

Despite a successful US launch of Antagy, Iovance Biotherapeutics Inc (IOVA) faces manufacturing hurdles and revises its revenue outlook.

GuruFocus.com 2 days ago

IOVA
-44.79%
Iovance Biotherapeutics (IOVA) Reports Q1 Loss, Misses Revenue Estimates

Iovance Biotherapeutics (IOVA) delivered earnings and revenue surprises of -44% and 38.73%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks 3 days ago

IOVA
-44.79%
Iovance Biotherapeutics: Q1 Earnings Snapshot

SAN CARLOS, Calif. AP) — Iovance Biotherapeutics Inc. IOVA) on Thursday reported a loss of $116.2 million in its first quarter.

Associated Press Finance 3 days ago

IOVA
-44.79%
Iovance Biotherapeutics Reports Financial Results and Corporate Updates for First Quarter 2025

1Q25 Total Product Revenue of $49.3M FY25 Total Product Revenue Guidance Revised to $250M-$300M FY25 Operating Expenses Reduced and 2H26 Cash Runway Guidance Maintained 2025 Regulatory Approvals for Amtagvi® Expected in the UK, EU, and Canada On Track to Report Updated Clinical Data for Registrational Trialin Previously Treated Advanced NSCLC in 2H25 SAN CARLOS, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on in

GlobeNewswire 3 days ago

IOVA
-44.79%
Iovance Biotherapeutics (NasdaqGM:IOVA) Sees 3% Price Increase Over Last Month

Iovance Biotherapeutics (NasdaqGM:IOVA) saw a 3% increase in its share price over the last month. This rise occurred amidst mixed market conditions where broader indices displayed minimal movement, as investors awaited crucial updates from the Federal Reserve on interest rates and tariff negotiations between the U.S. and China. Although the company-specific news remains undisclosed, the overall market sentiment, marked by volatility in tech stocks and investor cautiousness towards economic...

Simply Wall St. 4 days ago

IOVA
-44.79%
My 3 Favorite Stocks to Buy Right Now

There are plenty of good ones to choose from, but these three are all undervalued, leaving them ripe for a lot of bullishness sooner than later.

Motley Fool 5 days ago

AMZN

IOVA
-44.79%

PEP
Iovance Biotherapeutics to Host First Quarter 2025 Financial Results and Corporate Updates Webcast on Thursday, May 8, 2025

SAN CARLOS, Calif., May 02, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, will report its first quarter 2025 financial results and corporate updates on Thursday, May 8, 2025. Management will host a conference call and live audio webcast to discuss these results and provide a corporate update on May 8, 2025 at 4

GlobeNewswire 9 days ago

IOVA
-44.79%
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Is Expected To Breakeven In The Near Future

With the business potentially at an important milestone, we thought we'd take a closer look at Iovance Biotherapeutics...

Simply Wall St. 10 days ago

IOVA
-44.79%
2 Beaten-Down Stocks With Incredible Upside Potential

Iovance Biotherapeutics' lead medicine is generating growing sales and seeking plenty of label expansions. CRISPR Therapeutics has exciting gene-editing candidates in the works. Iovance Biotherapeutics (NASDAQ: IOVA) and CRISPR Therapeutics (NASDAQ: CRSP) are two incredibly innovative biotechs, but this hasn't translated into strong performances recently.

Motley Fool 11 days ago

IOVA
-44.79%

CRSP
Iovance Biotherapeutics Announces Participation in Upcoming Scientific Congresses

SAN CARLOS, Calif., April 23, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, announced that pre-clinical data for IOV-5001, a genetically engineered, inducible, and tethered interleukin-12 (IL-12) TIL cell therapy, will be presented at the 2025 AACR Annual Meeting. In addition, five-year outcomes data from the C

GlobeNewswire 18 days ago

IOVA
-44.79%
This Biotech Stock Could Be the Best Investment of the Decade

There's an incredible growth story hiding in plain sight for investors who can look to the future.

Motley Fool 22 days ago

IOVA
-44.79%
Is Iovance Biotherapeutics (IOVA) the Most Promising Penny Stock According to Analysts?

We recently published a list of the 11 Most Promising Penny Stocks According to Analysts. In this article, we are going to take a look at where Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) stands against other promising penny stocks. Solus’ Dan Greenhaus, and Invesco’s Brian Levitt together appeared on CNBC’s ‘Closing Bell’ on April 15 to talk […]

Insider Monkey 23 days ago

IOVA
-44.79%
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

SAN CARLOS, Calif., April 18, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer, today announced that on April 17, 2025 (the “Date of Grant”), the Company approved the grant of inducement stock options covering an aggregate of 297,600 shares of Iovance’s common stock to fifty new, non-

GlobeNewswire 23 days ago

IOVA
-44.79%
Is Iovance Biotherapeutics Inc. (NASDAQ:IOVA) the Best Biotech Penny Stock to Buy According to Hedge Funds?

We recently published a list of the 13 Best Biotech Penny Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where Iovance Biotherapeutics Inc. (NASDAQ:IOVA) stands against other biotech penny stocks. Peter Marks’s departure from the FDA has left innovators concerned regarding the current state of […]

Insider Monkey 25 days ago

IOVA
-44.79%
Is Iovance Biotherapeutics a Millionaire-Maker?

Iovance Biotherapeutics (NASDAQ: IOVA) just might be the right kind of biotech stock. The company has already achieved success. To appreciate Iovance's opportunity, we need to first gain a basic understanding of the company's primary scientific focus.

Motley Fool 27 days ago

IOVA
-44.79%

Performance Overview

Return	IOVA	S&P 500 (^GSPC)
YTD	-76.35%	-3.77%
1-Year	-86.99%	+8.55%
3-Year	-86.61%	+41.81%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Iovance Biotherapeutics, Inc. (IOVA)

3 Monster Stocks in the Making

Iovance Biotherapeutics First Quarter 2025 Earnings: Misses Expectations

Iovance Biotherapeutics Stock Sinks 46%. Here’s Why the Biotech Is Tumbling.

Why Iovance Biotherapeutics Stock Is Crashing Today

Iovance's Q1 Earnings & Sales Miss, Stock Slides 39% on '25 View Cut

Iovance Biotherapeutics Inc (IOVA) Q1 2025 Earnings Call Highlights: Strong Revenue from Antagy ...

Iovance Biotherapeutics (IOVA) Reports Q1 Loss, Misses Revenue Estimates

Iovance Biotherapeutics: Q1 Earnings Snapshot

Iovance Biotherapeutics Reports Financial Results and Corporate Updates for First Quarter 2025

Iovance Biotherapeutics (NasdaqGM:IOVA) Sees 3% Price Increase Over Last Month

My 3 Favorite Stocks to Buy Right Now

Iovance Biotherapeutics to Host First Quarter 2025 Financial Results and Corporate Updates Webcast on Thursday, May 8, 2025

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Is Expected To Breakeven In The Near Future

2 Beaten-Down Stocks With Incredible Upside Potential

Iovance Biotherapeutics Announces Participation in Upcoming Scientific Congresses

This Biotech Stock Could Be the Best Investment of the Decade

Is Iovance Biotherapeutics (IOVA) the Most Promising Penny Stock According to Analysts?

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Is Iovance Biotherapeutics Inc. (NASDAQ:IOVA) the Best Biotech Penny Stock to Buy According to Hedge Funds?

Is Iovance Biotherapeutics a Millionaire-Maker?

Performance Overview